Healthcare
Therapeutic Solutions International, Inc.(TSOI)
Live Price
Offline$0.0001
+0.00% today
1Y Change
-50.00%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- โ
- Revenue Growth
- -52.1%
- EPS Growth
- +53.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Therapeutic Solutions International, Inc. (TSOI) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 50.0% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -52.1%, EPS growth of +53.3%, a dividend yield of 0.0%. What stands out right now is revenue -52.1%, EPS +53.3%, free cash flow -5.2% with operating margin -2006.7% and ROIC -91.5%. Valuation sits in the middle of the pack at price/sales 5.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TSOI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-52.1% vs +7.6% peer median
Operating Margin
Below sector median
-2006.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on Nov 18, 2025, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -52.1% and EPS is at +53.3%, with operating margin around -2006.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -16.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Nov 18, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Aug 22, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 May 29, 2025 | โ | -25.0% | -50.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TSOI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TSOI Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TSOI and SPY.
Company Overview
Therapeutic Solutions International, Inc.
Other OTC
Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, traumatic brain injury, and lung pathologies, as well as for daily health. Its flagship products include QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and healthy cytokine production. The company also produces nutraceuticals, including ProJuvenol, a synergistic blend of complex anti-aging ingredients in capsules; NanoStilbene, a nanoemulsion of nanoparticle pterostilbene; DermalStilbene, a topical form of pterostilbene delivered through spray application onto skin; IsoStilbene, an injectable formulation of pterostilbene; NeuroStilbene, an intranasal form of pterostilbene; NanoPlus, a blend of NanoStilbene and Nano Cannabidiol; Nano Cannabidiol, a nanoparticle formulation of cannabidiol; NanoPSA, a blend of NanoStilbene and broccoli sprout extract; and NLRP3 Trifecta, a two-product combo that consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract. It is also developing therapeutics in chronic traumatic encephalopathy, and traumatic brain injury and lung pathology. Therapeutic Solutions International, Inc. was founded in 2007 and is based in Elk City, Idaho.
- Leadership
- Timothy George Dixon
- IPO Date
- Jun 24, 2008
- Employees
- 3
- Street Address
- 701 Wild Rose Lane
- Mailing
- Elk City, ID, 83525
- Region
- Elk City, ID, US
- Reporting Currency
- USD
- Investor Line
- 760 295 7208
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 5.2
- Price/Book
- 0.3
Growth
- Revenue
- -52.1%
- EPS
- +53.3%
- Free Cash Flow
- -5.2%
Profitability
- Gross Margin
- 62.9%
- Operating Margin
- -2006.7%
- Net Margin
- -2191.9%
- ROE
- -184.9%
- ROIC
- -91.5%
Balance Sheet
- Debt/Equity
- 0.79
- Current Ratio
- 0.05
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.